Moderna (LTS:0A45) FCF Yield % : -24.58 (As of Dec. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Moderna FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Moderna's Trailing 12-Month Free Cash Flow is $-3,956 Mil, and Market Cap is $16,097 Mil. Therefore, Moderna's FCF Yield % for today is -24.58%.

The historical rank and industry rank for Moderna's FCF Yield % or its related term are showing as below:

LTS:0A45' s FCF Yield % Range Over the Past 10 Years
Min: -26.91 Med: -1.66 Max: 24.06
Current: -24.58

During the past 8 years, the highest FCF Yield % of Moderna was 24.06%. The lowest was -26.91%. And the median was -1.66%.

LTS:0A45's FCF Yield % is ranked worse than
62.77% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs LTS:0A45: -24.58

Moderna's FCF Margin % for the quarter that ended in Sep. 2024 was -92.56%.

Moderna FCF Yield % Historical Data

The historical data trend for Moderna's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna FCF Yield % Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

4.71

13.27

6.72

-10.12

Moderna Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Yield %	Get a 7-Day Free Trial															-17.90	4.25	-11.54	-12.49	-26.55

Competitive Comparison of Moderna's FCF Yield %

For the Biotechnology subindustry, Moderna's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Moderna's FCF Yield % falls into.

Moderna FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Moderna's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-3825	/	37793.17
	=	-10.12%

Moderna's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1717	*	4	/	25866.225
	=	-26.55%

Moderna FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Moderna FCF Yield % Related Terms

Thank you for viewing the detailed overview of Moderna's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 1MRNA:Italy 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Headlines

No Headlines